Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander C Egilman

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
BMJ Evidence-Based Medicine|November 23, 2019
Digital medicine systems: an evergreening strategy or an advance in medication management?Alexander C Egilman, Joseph S Ross
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|August 24, 2021
Optimizing the data available via Health Canada's clinical information portalAlexander C Egilman, Joseph S Ross, Matthew Herder
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|October 19, 2021
Alexander C Egilman, Joseph S Ross, Matthew Herder
JAMA|October 4, 2022
Recent Trends in Prescription Drug Launch Prices-ReplyBenjamin N Rome, Alexander C Egilman, Aaron S Kesselheim
JAMA|June 7, 2022
Trends in Prescription Drug Launch Prices, 2008-2021Benjamin N Rome, Alexander C Egilman, Aaron S Kesselheim
Health Services Research|July 14, 2025
Share of Sales Subject to Medicare Inflation Rebates and Price Increases of Top-Selling DrugsAlexander C Egilman, Aaron S Kesselheim, Benjamin N Rome
JAMA|April 18, 2023
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in MedicareAlexander C Egilman, Benjamin N Rome, Aaron S Kesselheim
JAMA|January 3, 2023
Estimated Medicare Part B Savings From Inflationary RebatesAlexander C Egilman, Aaron S Kesselheim, Benjamin N Rome
JAMA|August 15, 2023
Gauging the Value of Top-Selling Drugs in Medicare-ReplyAlexander C Egilman, Benjamin N Rome, Aaron S Kesselheim
JAMA Network Open|April 4, 2025
Therapeutic Benefit of Top-Selling Oncology Drugs in MedicareStephanie Wang, Alexander C Egilman, Georg Hahn, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
BMJ Evidence-Based Medicine|November 23, 2019
Digital medicine systems: an evergreening strategy or an advance in medication management?Alexander C Egilman, Joseph S Ross
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|August 24, 2021
Optimizing the data available via Health Canada's clinical information portalAlexander C Egilman, Joseph S Ross, Matthew Herder
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|October 19, 2021
Alexander C Egilman, Joseph S Ross, Matthew Herder
JAMA|October 4, 2022
Recent Trends in Prescription Drug Launch Prices-ReplyBenjamin N Rome, Alexander C Egilman, Aaron S Kesselheim
JAMA|June 7, 2022
Trends in Prescription Drug Launch Prices, 2008-2021Benjamin N Rome, Alexander C Egilman, Aaron S Kesselheim
Health Services Research|July 14, 2025
Share of Sales Subject to Medicare Inflation Rebates and Price Increases of Top-Selling DrugsAlexander C Egilman, Aaron S Kesselheim, Benjamin N Rome
JAMA|April 18, 2023
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in MedicareAlexander C Egilman, Benjamin N Rome, Aaron S Kesselheim
JAMA|January 3, 2023
Estimated Medicare Part B Savings From Inflationary RebatesAlexander C Egilman, Aaron S Kesselheim, Benjamin N Rome
JAMA|August 15, 2023
Gauging the Value of Top-Selling Drugs in Medicare-ReplyAlexander C Egilman, Benjamin N Rome, Aaron S Kesselheim
JAMA Network Open|April 4, 2025
Therapeutic Benefit of Top-Selling Oncology Drugs in MedicareStephanie Wang, Alexander C Egilman, Georg Hahn, et al.
Pageof 4